Alcon® Ex-PRESS® Glaucoma Filtration Device in Japanese Patients
- Conditions
- Glaucoma
- Interventions
- Device: Ex-PRESS® Glaucoma Filtration Device, Model P50PL
- Registration Number
- NCT02246777
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to assess the efficacy and safety of the Alcon Ex-PRESS® Glaucoma Filtration Device (Ex-PRESS) in Japanese subjects with normal tension glaucoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
- Diagnosis of normal tension glaucoma.
- Indicated for filtration surgery using Ex-PRESS®.
- Understand and provide Informed Consent.
- Other protocol-defined inclusion criteria may apply.
- Women who are pregnant, lactating, or planning to be pregnant during the study period.
- Diagnosis of angle closure glaucoma or secondary glaucoma.
- History of glaucoma surgery.
- Ophthalmologic surgery within the past 6 months.
- Difficulty with applanation tonometry measurement.
- Corneal dystrophy.
- Infectious/non-infectious conjunctivitis, keratitis, or uveitis in either eye.
- Severe blepharitis or dry eye.
- History of metal allergy.
- Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ex-PRESS Ex-PRESS® Glaucoma Filtration Device, Model P50PL Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
- Primary Outcome Measures
Name Time Method Percentage of Eyes With IOP Lowering Rate of 20% or More From Baseline up to Month 12 Baseline (Pre-Operative), Month 3, Month 6, Month 12 Post-Operative IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
Percent Change From Baseline in IOP Baseline (Pre-Operative), Month 3, Month 6, Month 12 Post-Operative IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative percent change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye contributed to the analysis.
Change From Baseline in IOP Baseline (Pre-Operative), Month 3, Month 6, Month 12 Post-Operative IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye contributed to the analysis.
Percentage of Eyes Receiving Secondary Surgical Treatment (Including Laser Therapy) Necessary to Maintain the IOP Month 3, Month 6, Month 12 Post-Operative IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Secondary surgical treatment included needling, laser suture lysis, and conjunctival and scleral flap sutures. For some subjects, both left and right eyes were targeted for the study, and data from both eyes were analyzed for this safety endpoint, as specified in the protocol. An eye may have received more than one procedure.
Mean Intraocular Pressure (IOP) Month 3, Month 6, Month 12 Post-Operative IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
Percentage of Eyes Receiving Drug Therapy for Glaucoma Necessary to Maintain the IOP Month 3, Month 6, Month 12 Post-Operative IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). For some subjects, both left and right eyes were targeted for the study, and data from both eyes were analyzed for this safety endpoint, as specified in the protocol.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Contact Alcon Japan, Ltd for Trial Locations
🇯🇵Tokyo, Japan